Financials Prenetics Global Limited

Equities

PRE

KYG722451229

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-04-26 pm EDT 5-day change 1st Jan Change
4.61 USD -7.24% Intraday chart for Prenetics Global Limited +58.97% -22.00%

Valuation

Fiscal Period: December 2021 2022 2023 2024 2025
Capitalization 1 - 222 55.4 55.4 -
Enterprise Value (EV) 1 - 222 55.4 55.4 55.4
P/E ratio -0.83 x -0.8 x -0.22 x -1.28 x -6.23 x
Yield - - - - -
Capitalization / Revenue - 0.8 x 1.55 x 1.57 x 0.62 x
EV / Revenue - 0.8 x 1.55 x 1.57 x 0.62 x
EV / EBITDA - 3,806,278 x - - -
EV / FCF - - - - -
FCF Yield - - - - -
Price to Book - - - - -
Nbr of stocks (in thousands) - 7,399 12,018 12,018 -
Reference price 2 115.2 30.00 4.610 4.610 4.610
Announcement Date 4/11/22 3/14/23 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2021 2022 2023 2024 2025
Net sales 1 - 275.8 35.8 35.2 90
EBITDA - 58.31 - - -
EBIT 1 - -23.3 -50.2 -47 -12.6
Operating Margin - -8.45% -140.22% -133.52% -14%
Earnings before Tax (EBT) 1 - -183.3 -56.67 -47 -12.6
Net income 1 -174 -190.5 -48.8 -47 -10.4
Net margin - -69.06% -136.31% -133.52% -11.56%
EPS 2 -138.6 -37.50 -21.15 -3.590 -0.7400
Free Cash Flow - - - - -
FCF margin - - - - -
FCF Conversion (EBITDA) - - - - -
FCF Conversion (Net income) - - - - -
Dividend per Share - - - - -
Announcement Date 4/11/22 3/14/23 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1
Net sales 1 92.04 51.72 79.68 52.32 17.7 22.67 10.2 7.5 6.2
EBITDA - - - - - - - - -
EBIT 1 -0.5507 -17.9 -9.485 4.63 -12.04 -9.91 -12 -12.4 -12.6
Operating Margin -0.6% -34.61% -11.9% 8.85% -68.05% -43.71% -117.65% -165.33% -203.23%
Earnings before Tax (EBT) 1 -31.32 -143.9 -11.4 3.323 -10.98 -11.16 -6.43 -12.4 -12.6
Net income 1 -32.99 -144.2 -14.9 1.608 -10.4 -10.05 -12 -11.1 -12.6
Net margin -35.84% -278.78% -18.7% 3.07% -58.75% -44.33% -117.65% -148% -203.23%
EPS 2 -33.15 -20.40 -3.150 0.1500 -1.050 -0.9000 -1.200 -4.800 -1.020
Dividend per Share - - - - - - - - -
Announcement Date 6/6/22 9/9/22 11/10/22 3/14/23 6/5/23 - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2021 2022 2023 2024 2025
Net Debt - - - - -
Net Cash position - - - - -
Leverage (Debt/EBITDA) - - - - -
Free Cash Flow - - - - -
ROE (net income / shareholders' equity) - - - - -
ROA (Net income/ Total Assets) - - - - -
Assets 1 - - - - -
Book Value Per Share - - - - -
Cash Flow per Share - - - - -
Capex - 4.95 - - -
Capex / Sales - 1.79% - - -
Announcement Date 4/11/22 3/14/23 - - -
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
4.61 USD
Average target price
9 USD
Spread / Average Target
+95.23%
Consensus
  1. Stock Market
  2. Equities
  3. PRE Stock
  4. Financials Prenetics Global Limited